Loading…

The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic

The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medicati...

Full description

Saved in:
Bibliographic Details
Published in:Annals of family medicine 2024-09, Vol.22 (5), p.444-450
Main Authors: Zittleman, Linda, Westfall, John M, Sofie, Benjamin, Lutgen, Cory, Fernald, Douglas, Hall, Tristen L, Hochheimer, Camille J, Murphy, Melanie, Felzien, Maret, Dickinson, L Miriam, Manning, Brian K, LeMaster, Joseph, Nease, Jr, Donald E
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 450
container_issue 5
container_start_page 444
container_title Annals of family medicine
container_volume 22
creator Zittleman, Linda
Westfall, John M
Sofie, Benjamin
Lutgen, Cory
Fernald, Douglas
Hall, Tristen L
Hochheimer, Camille J
Murphy, Melanie
Felzien, Maret
Dickinson, L Miriam
Manning, Brian K
LeMaster, Joseph
Nease, Jr, Donald E
description The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.
doi_str_mv 10.1370/afm.3149
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11419717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A813056920</galeid><sourcerecordid>A813056920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-3a4558b09e1514d66c5e5fa0acc6cc079da9f0f7e1ebc96e6650ac45a0e6d83e3</originalsourceid><addsrcrecordid>eNptklFr2zAUhc3YWLtusF8wBIOxF2dSZMnRXkZJsrXQ4lHavQpFvoo1bCmV7ELon6-8ZqGBoAdddD-di45Oln0keEJoib8p000oKcSr7JSwoshJScrX-xqLk-xdjH8xnpIpnb7NTqighFJGT7PH2wZQVW9jhC3yBl1U18ub72juu40KqrcPgJbGgB4rBzGiG4iggm6Qd-gaaqsTlErjA6o21tsa3UVACxt9qCGgxRCsW6M-TZlXfy4XORHot3I1dFa_z94Y1Ub4sNvPsrufy9v5RX5V_bqcn1_lusC4z6kqGJutsADCSFFzrhkwo7DSmmuNS1ErYbApgcBKCw6cs9QrmMLA6xkFepb9eNbdDKsOag2uD6qVm2A7FbbSKysPO842cu0fJCEFEcnKpPB1pxD8_QCxl52NGtpWOfBDlJTgWckp5Tihn5_RtWpBWmd8ktQjLs9nhGLGxXSk8iPUOlmc5nsHxqbjA35yhE_rn5FHL3x5caEB1fZN9O0wflY8BHdP08HHGMDsfSFYjuGSKVxyDFdCP730cQ_-TxN9AjAZyBs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3108763360</pqid></control><display><type>article</type><title>The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic</title><source>PubMed Central</source><creator>Zittleman, Linda ; Westfall, John M ; Sofie, Benjamin ; Lutgen, Cory ; Fernald, Douglas ; Hall, Tristen L ; Hochheimer, Camille J ; Murphy, Melanie ; Felzien, Maret ; Dickinson, L Miriam ; Manning, Brian K ; LeMaster, Joseph ; Nease, Jr, Donald E</creator><creatorcontrib>Zittleman, Linda ; Westfall, John M ; Sofie, Benjamin ; Lutgen, Cory ; Fernald, Douglas ; Hall, Tristen L ; Hochheimer, Camille J ; Murphy, Melanie ; Felzien, Maret ; Dickinson, L Miriam ; Manning, Brian K ; LeMaster, Joseph ; Nease, Jr, Donald E</creatorcontrib><description>The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.</description><identifier>ISSN: 1544-1709</identifier><identifier>ISSN: 1544-1717</identifier><identifier>EISSN: 1544-1717</identifier><identifier>DOI: 10.1370/afm.3149</identifier><identifier>PMID: 39313353</identifier><language>eng</language><publisher>United States: Annals of Family Medicine</publisher><subject>Buprenorphine ; Buprenorphine - therapeutic use ; Care and treatment ; Colorado ; Comparative analysis ; Comparative Effectiveness Research ; COVID-19 - epidemiology ; Dosage and administration ; Drugs ; Epidemics ; Evidence-based medicine ; Family medicine ; Greek mythology ; Humans ; Medical research ; Medical societies ; Medicine, Experimental ; Narcotic Antagonists - therapeutic use ; Opiate Substitution Treatment - methods ; Opioid-Related Disorders - drug therapy ; Pandemics ; Patient outcomes ; Pharmacology, Experimental ; Primary Health Care ; SARS-CoV-2 ; Social aspects ; Special Report ; Telemedicine</subject><ispartof>Annals of family medicine, 2024-09, Vol.22 (5), p.444-450</ispartof><rights>2024 Annals of Family Medicine, Inc.</rights><rights>COPYRIGHT 2024 Annals of Family Medicine</rights><rights>2024 Annals of Family Medicine, Inc. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419717/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419717/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39313353$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zittleman, Linda</creatorcontrib><creatorcontrib>Westfall, John M</creatorcontrib><creatorcontrib>Sofie, Benjamin</creatorcontrib><creatorcontrib>Lutgen, Cory</creatorcontrib><creatorcontrib>Fernald, Douglas</creatorcontrib><creatorcontrib>Hall, Tristen L</creatorcontrib><creatorcontrib>Hochheimer, Camille J</creatorcontrib><creatorcontrib>Murphy, Melanie</creatorcontrib><creatorcontrib>Felzien, Maret</creatorcontrib><creatorcontrib>Dickinson, L Miriam</creatorcontrib><creatorcontrib>Manning, Brian K</creatorcontrib><creatorcontrib>LeMaster, Joseph</creatorcontrib><creatorcontrib>Nease, Jr, Donald E</creatorcontrib><title>The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic</title><title>Annals of family medicine</title><addtitle>Ann Fam Med</addtitle><description>The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.</description><subject>Buprenorphine</subject><subject>Buprenorphine - therapeutic use</subject><subject>Care and treatment</subject><subject>Colorado</subject><subject>Comparative analysis</subject><subject>Comparative Effectiveness Research</subject><subject>COVID-19 - epidemiology</subject><subject>Dosage and administration</subject><subject>Drugs</subject><subject>Epidemics</subject><subject>Evidence-based medicine</subject><subject>Family medicine</subject><subject>Greek mythology</subject><subject>Humans</subject><subject>Medical research</subject><subject>Medical societies</subject><subject>Medicine, Experimental</subject><subject>Narcotic Antagonists - therapeutic use</subject><subject>Opiate Substitution Treatment - methods</subject><subject>Opioid-Related Disorders - drug therapy</subject><subject>Pandemics</subject><subject>Patient outcomes</subject><subject>Pharmacology, Experimental</subject><subject>Primary Health Care</subject><subject>SARS-CoV-2</subject><subject>Social aspects</subject><subject>Special Report</subject><subject>Telemedicine</subject><issn>1544-1709</issn><issn>1544-1717</issn><issn>1544-1717</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNptklFr2zAUhc3YWLtusF8wBIOxF2dSZMnRXkZJsrXQ4lHavQpFvoo1bCmV7ELon6-8ZqGBoAdddD-di45Oln0keEJoib8p000oKcSr7JSwoshJScrX-xqLk-xdjH8xnpIpnb7NTqighFJGT7PH2wZQVW9jhC3yBl1U18ub72juu40KqrcPgJbGgB4rBzGiG4iggm6Qd-gaaqsTlErjA6o21tsa3UVACxt9qCGgxRCsW6M-TZlXfy4XORHot3I1dFa_z94Y1Ub4sNvPsrufy9v5RX5V_bqcn1_lusC4z6kqGJutsADCSFFzrhkwo7DSmmuNS1ErYbApgcBKCw6cs9QrmMLA6xkFepb9eNbdDKsOag2uD6qVm2A7FbbSKysPO842cu0fJCEFEcnKpPB1pxD8_QCxl52NGtpWOfBDlJTgWckp5Tihn5_RtWpBWmd8ktQjLs9nhGLGxXSk8iPUOlmc5nsHxqbjA35yhE_rn5FHL3x5caEB1fZN9O0wflY8BHdP08HHGMDsfSFYjuGSKVxyDFdCP730cQ_-TxN9AjAZyBs</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Zittleman, Linda</creator><creator>Westfall, John M</creator><creator>Sofie, Benjamin</creator><creator>Lutgen, Cory</creator><creator>Fernald, Douglas</creator><creator>Hall, Tristen L</creator><creator>Hochheimer, Camille J</creator><creator>Murphy, Melanie</creator><creator>Felzien, Maret</creator><creator>Dickinson, L Miriam</creator><creator>Manning, Brian K</creator><creator>LeMaster, Joseph</creator><creator>Nease, Jr, Donald E</creator><general>Annals of Family Medicine</general><general>American Academy of Family Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240901</creationdate><title>The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic</title><author>Zittleman, Linda ; Westfall, John M ; Sofie, Benjamin ; Lutgen, Cory ; Fernald, Douglas ; Hall, Tristen L ; Hochheimer, Camille J ; Murphy, Melanie ; Felzien, Maret ; Dickinson, L Miriam ; Manning, Brian K ; LeMaster, Joseph ; Nease, Jr, Donald E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-3a4558b09e1514d66c5e5fa0acc6cc079da9f0f7e1ebc96e6650ac45a0e6d83e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Buprenorphine</topic><topic>Buprenorphine - therapeutic use</topic><topic>Care and treatment</topic><topic>Colorado</topic><topic>Comparative analysis</topic><topic>Comparative Effectiveness Research</topic><topic>COVID-19 - epidemiology</topic><topic>Dosage and administration</topic><topic>Drugs</topic><topic>Epidemics</topic><topic>Evidence-based medicine</topic><topic>Family medicine</topic><topic>Greek mythology</topic><topic>Humans</topic><topic>Medical research</topic><topic>Medical societies</topic><topic>Medicine, Experimental</topic><topic>Narcotic Antagonists - therapeutic use</topic><topic>Opiate Substitution Treatment - methods</topic><topic>Opioid-Related Disorders - drug therapy</topic><topic>Pandemics</topic><topic>Patient outcomes</topic><topic>Pharmacology, Experimental</topic><topic>Primary Health Care</topic><topic>SARS-CoV-2</topic><topic>Social aspects</topic><topic>Special Report</topic><topic>Telemedicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zittleman, Linda</creatorcontrib><creatorcontrib>Westfall, John M</creatorcontrib><creatorcontrib>Sofie, Benjamin</creatorcontrib><creatorcontrib>Lutgen, Cory</creatorcontrib><creatorcontrib>Fernald, Douglas</creatorcontrib><creatorcontrib>Hall, Tristen L</creatorcontrib><creatorcontrib>Hochheimer, Camille J</creatorcontrib><creatorcontrib>Murphy, Melanie</creatorcontrib><creatorcontrib>Felzien, Maret</creatorcontrib><creatorcontrib>Dickinson, L Miriam</creatorcontrib><creatorcontrib>Manning, Brian K</creatorcontrib><creatorcontrib>LeMaster, Joseph</creatorcontrib><creatorcontrib>Nease, Jr, Donald E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of family medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zittleman, Linda</au><au>Westfall, John M</au><au>Sofie, Benjamin</au><au>Lutgen, Cory</au><au>Fernald, Douglas</au><au>Hall, Tristen L</au><au>Hochheimer, Camille J</au><au>Murphy, Melanie</au><au>Felzien, Maret</au><au>Dickinson, L Miriam</au><au>Manning, Brian K</au><au>LeMaster, Joseph</au><au>Nease, Jr, Donald E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic</atitle><jtitle>Annals of family medicine</jtitle><addtitle>Ann Fam Med</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>22</volume><issue>5</issue><spage>444</spage><epage>450</epage><pages>444-450</pages><issn>1544-1709</issn><issn>1544-1717</issn><eissn>1544-1717</eissn><abstract>The usual challenges of conducting primary care research, including randomized trials, have been exacerbated, and new ones identified, during the COVID-19 pandemic. HOMER (Home versus Office for Medication Enhanced Recovery; subsequently, Comparing Home, Office, and Telehealth Induction for Medication Enhanced Recovery) is a pragmatic, comparative-effectiveness research trial that aims to answer a key question from patients and clinicians: What is the best setting in which to start treatment with buprenorphine for opioid use disorder for this patient at this time? In this article, we describe the difficult journey to find the answer. The HOMER study began as a randomized trial comparing treatment outcomes in patients starting treatment with buprenorphine via induction at home (unobserved) vs in the office (observed, synchronous). The study aimed to enroll 1,000 participants from 100 diverse primary care practices associated with the State Networks of Colorado Ambulatory Practices and Partners and the American Academy of Family Physicians National Research Network. The research team faced unexpected challenges related to the COVID-19 pandemic and dramatic changes in the opioid epidemic. These challenges required changes to the study design, protocol, recruitment intensity, and funding conversations, as well as patience. As this is a participatory research study, we sought, documented, and responded to practice and patient requests for adaptations. Changes included adding a third study arm using telehealth induction (observed via telephone or video, synchronous) and switching to a comprehensive cohort design to answer meaningful patient-centered research questions. Using a narrative approach based on the Greek myth of Homer, we describe here the challenges and adaptations that have provided the opportunity for HOMER to thrive and find the way home. These clinical trial strategies may apply to other studies faced with similar cultural and extreme circumstances.</abstract><cop>United States</cop><pub>Annals of Family Medicine</pub><pmid>39313353</pmid><doi>10.1370/afm.3149</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1544-1709
ispartof Annals of family medicine, 2024-09, Vol.22 (5), p.444-450
issn 1544-1709
1544-1717
1544-1717
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11419717
source PubMed Central
subjects Buprenorphine
Buprenorphine - therapeutic use
Care and treatment
Colorado
Comparative analysis
Comparative Effectiveness Research
COVID-19 - epidemiology
Dosage and administration
Drugs
Epidemics
Evidence-based medicine
Family medicine
Greek mythology
Humans
Medical research
Medical societies
Medicine, Experimental
Narcotic Antagonists - therapeutic use
Opiate Substitution Treatment - methods
Opioid-Related Disorders - drug therapy
Pandemics
Patient outcomes
Pharmacology, Experimental
Primary Health Care
SARS-CoV-2
Social aspects
Special Report
Telemedicine
title The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A33%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Odyssey%20of%20HOMER:%20Comparative%20Effectiveness%20Research%20on%20Medication%20for%20Opioid%20Use%20Disorder%20During%20the%20COVID-19%20Pandemic&rft.jtitle=Annals%20of%20family%20medicine&rft.au=Zittleman,%20Linda&rft.date=2024-09-01&rft.volume=22&rft.issue=5&rft.spage=444&rft.epage=450&rft.pages=444-450&rft.issn=1544-1709&rft.eissn=1544-1717&rft_id=info:doi/10.1370/afm.3149&rft_dat=%3Cgale_pubme%3EA813056920%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-3a4558b09e1514d66c5e5fa0acc6cc079da9f0f7e1ebc96e6650ac45a0e6d83e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3108763360&rft_id=info:pmid/39313353&rft_galeid=A813056920&rfr_iscdi=true